Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma

Inclusion Criteria:

* Previously untreated mantle cell lymphoma patients (at least clinical stage 2)
* Histologic diagnosis confirmed by MSKCC pathologist as mantle cell lymphoma
* Presence of evaluable disease
* Age ≥18 years KPS ≥ 70%
* Adequate organ function: ANC ≥1500 and platelet count ≥100,000, unless felt to be secondary to underlying mantle cell lymphoma
* Renal function assessed by calculated creatinine clearance as follows:
* Cockcroft-Gault estimation of CrCl):

  * Calculated creatinine clearance ≥ 30ml/min by Cockcroft-Gault formula. See section below, "Dosing Regimen", regarding lenalidomide dose adjustment for calculated creatinine clearance ≥30ml/min and \< 60ml/min.
* Adequate hepatic function as determined by

  * Total bilirubin \<1.5X upper limit of normal (ULN) (unless known Gilbert syndrome)
  * AST (SGOT) and ALT (SGPT) 3 x ULN
* All study participants must be registered into the mandatory Revlimid REMS® program, and be willing and able to comply with the requirements of the REMS® program.
* Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS® program.
* Each subject must sign an informed consent form indicating that he or she understand the purpose of and procedures required for the study and are willing to participate.
* Short course systemic corticosteroids is permissible for disease control, improvement of performance status or non-cancer indication if ≤ 10 days and must be discontinued prior to study treatment.

Exclusion Criteria:

* Known central nervous system (CNS) lymphoma
* Uncontrolled or severe cardiovascular disease or left ventricular ejection fraction \<50% as determined by echocardiogram or MUGA.
* Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk.
* Pregnant or breast-feeding. Pre-menopausal patients must have a negative serum HCG within 14 days of enrollment.
* Patients using ≥20 mg/day of prednisone (or steroid equivalent dose) for any chronic medical condition
* Known seropositive, requiring anti-viral therapy, and with detectable viral load by PCR for human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV).
* Known hypersensitivity to thalidomide or lenalidomide
* The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.
* Patients planned for upfront consolidation with high-dose therapy and autologous stem cell transplant.